Methods of treating age-related and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-12115191-B2
Application number	US-202117174259-A
Country	US
Kind code	B2
Filing date	Feb 11, 2021
Priority date	Feb 11, 2020
Publication date	Oct 15, 2024
Grant date	Oct 15, 2024

Abstract

Provided herein are methods of treating an aging-related disease or inflammatory disease in a subject that include (i) a therapeutically effective amount of an NK cell activating agent and/or an NK cell and/or monoclonal antibody; and (ii) a therapeutically effective amount of a Treg cell activating agent and/or a Treg cell and/or a monoclonal antibody and/or AGE inhibitor.

First claim

What is claimed is:

1. A method of treating cancer in a subject, the method comprising administering to the subject:
(i) a therapeutically effective amount of a multi-chain chimeric polypeptide; and
(ii) a therapeutically effective amount of an anti-CD36 monoclonal antibody,
wherein the multi-chain chimeric polypeptide comprises:
(a) a first chimeric polypeptide comprising:
a first target-binding domain consisting of a sequence that is at least 90% identical to SEQ ID NO: 109;
a soluble tissue factor domain consisting of a sequence that is at least 90% identical to SEQ ID NO: 8; and
a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO: 22; and

(b) a second chimeric polypeptide comprising:
a second target-binding domain consisting of a sequence that is at least 90% identical to SEQ ID NO: 109; and
a second domain of a pair of affinity domains consisting of a sequence that is at least 90% identical to SEQ ID NO: 36,

wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains.

2. The method of claim 1 , wherein (i) is administered to the subject at substantially the same time as (ii).

3. The method of claim 1 , wherein (i) is administered to the subject prior to administration of (ii) to the subject.

4. The method of claim 1 , wherein (ii) is administered to the subject prior to administration of (i) to the subject.

5. The method of claim 1 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other in the first chimeric polypeptide.

6. The method of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain in the first chimeric polypeptide.

7. The method of claim 1 , wherein the soluble tissue factor domain and the first domain of the pair of affinity domains directly abut each other in the first chimeric polypeptide.

8. The method of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the pair of affinity domains in the first chimeric polypeptide.

9. The method of claim 1 , wherein the second domain of the pair of affinity domains and the second target-binding domain directly abut each other in the second chimeric polypeptide.

10. The method of claim 1 , wherein the second chimeric polypeptide further comprises a linker sequence between the second domain of the pair of affinity domains and the second target-binding domain in the second chimeric polypeptide.

11. The method of claim 1 , wherein the soluble tissue factor domain is a soluble human tissue factor domain.

12. The method of claim 1 , wherein the multi-chain chimeric polypeptide does not stimulate blood coagulation in a mammal.

13. The method of claim 1 , wherein:
the first target-binding domain consists of a sequence that is at least 95% identical to SEQ ID NO: 109;
the soluble tissue factor domain consists of a sequence that is at least 95% identical to SEQ ID NO: 8;
the first domain of the pair of affinity domains consists of a sequence that is at least 95% identical to SEQ ID NO: 22;
the second target-binding domain consists of a sequence that is at least 95% identical to SEQ ID NO: 109; and
the second domain of the pair of affinity domains consists of a sequence that is at least 95% identical to SEQ ID NO: 36.

14. The method of claim 1 , wherein:
the first target-binding domain consists of SEQ ID NO: 109;
the soluble tissue factor domain consists of SEQ ID NO: 8;
the first domain of the pair of affinity domains consists of SEQ ID NO: 22;
the second target-binding domain consists of SEQ ID NO: 109; and
the second domain of the pair of affinity domains consists of SEQ ID NO: 36.

15. The method of claim 1 , wherein:
the first chimeric polypeptide consists of a sequence that is at least 90% identical to SEQ ID NO: 111; and
the second chimeric polypeptide consists of a sequence that is at least 90% identical to SEQ ID NO: 115.

16. The method of claim 1 , wherein:
the first chimeric polypeptide consists of a sequence that is at least 96% identical to SEQ ID NO: 111; and
the second chimeric polypeptide consists of a sequence that is at least 96% identical to SEQ ID NO: 115.

17. The method of claim 1 , wherein:
the first chimeric polypeptide consists of SEQ ID NO: 111; and
the second chimeric polypeptide consists of SEQ ID NO: 115.

Assignees

• Immunitybio Inc

Inventors

• Wong Hing C

Classifications

• A61K40/4229

  Transforming growth factor [TGF] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• C07K14/435

  from animals; from humans · CPC title